Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

1,500 women join landmark study to stop molar pregnancy turning cancerous

NCT ID NCT07202728

Knowledge-focused Sponsor: Obstetrics & Gynecology Hospital of Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 1,489 women diagnosed with hydatidiform mole (molar pregnancy) across multiple hospitals in China. Researchers will track how often the condition becomes cancerous and look for ways to predict and prevent that. The goal is to create a nationwide system for better diagnosis and treatment, while also monitoring patients' mental health and future fertility.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better prediction and prevention of molar pregnancy turning into cancer, and more personalized care for patients.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may take years and might not change practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,489 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will enrol women with a confirmed hydatidiform mole who have undergone uterine evacuation. Candidates must possess complete clinical and pathological records and show no myometrial invasion or distant metastasis at baseline. We will exclude those with concurrent malignancy, severe autoimmune or infectious disease, or significant psychiatric illness. Longitudinal follow-up will track malignant transformation (post-molar gestational trophoblastic neoplasia per FIGO criteria), reproductive outcomes, and health-related quality of life. By establishing a large, nationwide, multicentre cohort, we aim to clarify the epidemiology, pinpoint risk factors for malignant progression, and evaluate long-term reproductive and psychosocial outcomes in this population.

Ages

18 to 60 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Clinically or pathologically diagnosed as hydatidiform mole. 2. Availability of complete medical records, including clinical and pathological data. 3. No evidence of myometrial invasion or metastasis. 4. Serum hCG levels normalized after uterine evacuation with at least 6 months of follow-up, OR diagnosed with postmolar gestational trophoblastic neoplasia (pGTN) during follow-up. 5. No history of psychiatric disorders, serious infectious diseases, or immune system diseases (such as systemic lupus erythematosus, myasthenia gravis, HIV infection, etc.). 6. Willing to participate in this study and sign the relevant informed consent form. Exclusion Criteria: 1. Missing clinical data. 2. Loss to follow-up: Do not return to participating hospital for follow-up visits after uterine evacuation, or could not be contacted for subsequent monitoring of hCG changes. 3. Concomitant malignancies or autoimmune deficiency disorders (e.g., systemic lupus erythematosus, myasthenia gravis, HIV infection, etc.). 4. As determined by the investigator, the presence of medical, psychological, social, occupational, or other conditions that would violate the study protocol or impair the subject's ability to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hydatidiform mole are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hydatidiform mole

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hydatidiform mole

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Center for Reproductive Medicine, Shandong University

    NOT_YET_RECRUITING

    Jinan, Shandong, 250021, China

  • Dalian Women and Children medical Center

    NOT_YET_RECRUITING

    Dalian, Liaoning, 116038, China

  • First Affiliated Hospital of Zhejiang University

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, 310003, China

  • Gansu Province Maternal and Child Care Hospital

    RECRUITING

    Lanzhou, Gansu, 730050, China

  • Hainan women and children medical center

    RECRUITING

    Haikou, Hainan, 570311, China

  • Hebei Medical University Third Hospital

    NOT_YET_RECRUITING

    Shijiazhuang, Hebei, 050051, China

  • International Peace Maternity and Child Health Hospital

    NOT_YET_RECRUITING

    Shanghai, 200030, China

  • Obstetrics & Gynecology Hospital of Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 200090, China

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, 100730, China

  • Shanghai First Maternity and Infant Hospital

    NOT_YET_RECRUITING

    Shanghai, Shandong, 201204, China

  • Shengjing Hospital of China Medical University

    NOT_YET_RECRUITING

    Shenyang, Liaoning, 110004, China

  • Shenzhen Maternity & Child Healthcare Hospital

    NOT_YET_RECRUITING

    Shenzhen, Guangdong, 518028, China

  • The Affiliated Hospital of Qingdao University

    NOT_YET_RECRUITING

    Qingdao, Shandong, 266000, China

  • Third Affiliated Hospital of Zhengzhou University

    NOT_YET_RECRUITING

    Zhengzhou, Henan, 450052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.